3 New Findings that Could Change Care

Last Updated on Thursday, February 13, 2014

By Eleni Z. Tsigas, Executive Director

Reporting from The Pregnancy Meeting™

We spent last week in New Orleans at the Society for Maternal-Fetal Medicine annual meeting, awaiting the results of the HYPITAT II study, and learned – probably to no one’s surprise – that expectant monitoring is recommended over immediate delivery for women with pregnancy-related hypertension between 34 and 37 weeks.

The first HYPITAT study – widely heralded for the size of the population it studied and therefore strength of its results – produced a somewhat controversial recommendation. Its findings suggested we should bail out of all pregnancies affected by pregnancy-related hypertension (e.g., preeclampsia, gestational hypertension) at 37 weeks, noting better outcomes for both mother and baby. This “immediate delivery” protocol has now been included in most management guidelines, though it is not without its critics. (We love our acronyms, don’t we? HYPITAT stands for Hypertension and Preeclampsia Intervention Trial At Term, and was a multi-center, randomized controlled trial in the Netherlands.)

This second study – HYPITAT II – reported at The Pregnancy Meeting™ – found that, for hypertensive mothers between 34 and 37 weeks of pregnancy, postponing delivery until the baby is no longer at risk for breathing difficulties, or until mother or child become too severely ill to wait any longer, produces better outcomes than immediate delivery. The challenge, of course, is defining “too severely ill” in a disorder that is often characterized by a constellation of symptoms. That, and the fact that preeclampsia can turn severe and life-threatening in a matter of hours, makes expectant management (i.e., monitoring) challenging for all but the most experienced obstetricians. Nonetheless, these findings indicated that taking a monitored “wait and see” approach may be the best practice for better outcomes.

In addition to this oral presentation during the opening plenary session, it was encouraging to see over 80 other talks and poster presentations on the topic of preeclampsia. Low dose aspirin is still being researched with results supporting both sides of the decision to offer this intervention for possible prevention of preeclampsia; quite a bit of mechanistic research was presented (i.e., the molecular “cause” of preeclampsia); and much more.

The scientific questions surrounding this complex disorder of pregnancy continue to intrigue and motivate researchers, which was heartening to see. More discouraging is what appears to be the snail’s pace and lack of large-scale clinical trials that are needed to move forward what we actually need to do for our preeclamptic women.

Is Vitamin D the Answer?

Other nutrition-based research on the relationship between low levels of Vitamin D and preeclampsia also came out recently, capturing widespread attention in the mainstream media. The research findings do not warrant a recommendation for widespread supplementation. The study’s author, Dr. Lisa Bodnar, clarifies that more research is needed. "It is important to remember that this was a study using data from the 1960s, and our population has changed in the subsequent 50 years. Therefore, I believe we need additional research on this topic using contemporary cohorts of women. If pregnant women are concerned about their vitamin D concentrations, they should talk with their health care provider and continue to take their prenatal vitamin."

California Toolkit Intends to Improve Quality of Care

Finally, Preeclampsia Foundation volunteer and The Promise Walk for Preeclampsia™ coordinator Elizabeth Barnett was featured in the San Francisco Chronicle’s story about the new management guidelines released by the California Maternal Quality Care Collaborative, “Improving Health Care Response to Preeclampsia: A California Quality Improvement Toolkit.”

We were thrilled that our website’s information and Barnett’s experience could be used to help educate readers about this life-threatening disorder of pregnancy and drive home the importance of healthcare providers improving diagnosis and management practices to reduce the death, illness and disabilities caused by preeclampsia.

The most compelling rationale for adopting the California Toolkit is that virtually all of the preeclampsia-related maternal deaths in California were found to have been most likely preventable. That means, we already know what to do to prevent moms from dying – we just need to ensure we diagnose and manage preeclampsia correctly, with every woman, everywhere, every time.

Press Releases by Year

Other Resources

Privacy Policy

Normal web site usageThe Preeclampsia Foundation has a firm commitment to Internet privacy. You can visit most portions of preeclampsia.org without telling us who you are and without revealing any personal information. The only information we collect from a normal web site visit is the name of your Internet Service Provider, the browser and type of machine you are using, the web site that referred you to us, the pages you request and the date and time you request them. We use this information to generate statistics and measure site activity to improve the usefulness of the site to our visitors.

Collection of personally identifiable informationThe Preeclampsia Foundation may collect names, email addresses and other personally identifiable data about visitors when such data is voluntarily submitted to preeclampsia.org. For example, our site uses forms for visitors to register or make a donation online. Contact information from these forms is used to send information about preeclampsia or Foundation activity to our visitors. Financial information is used to bill or provide receipts to visitors in connection with their donations. To ensure the security of credit card and personal information, this Web site employs industry-standard security methods, including the Secure Socket Layers (SSL) protocol for the encryption of transmitted data. The Preeclampsia Foundation goes to great lengths to protect the confidentiality and integrity of any personal information you share with us over the Internet. In instances where we may partner with medical organizations to conduct research on preeclampsia, your participation may be expressly requested, but your permission would be required prior to sharing personally identifiable data with authorized medical organizations.

The Preeclampsia Foundation makes every effort to ensure the secure collection and transmission of sensitive user information using industry accepted data collection and encryption methodologies.

Donor Privacy PolicyThe Preeclampsia Foundation does not sell or otherwise disclose user information outside the organization. We will not sell, trade or share a donor's personal information with anyone else, nor send donor mailings on behalf of other organizations.

Should you wish to review or make corrections to your personal information, please click Login/Join at the top of the page and enter your login information. A page titled "Edit Your Details" will appear in the main body of the page where you can view and make corrections. If you wish to be removed entirely from our database, please email info@preeclampsia.org.

CookiesWe do not use cookies on the majority of our website pages. The donate pages do use "per session" cookies. Per session cookies last only for the life of your current browser load and use no permanent storage on your hard drive. The use of per session cookies is very common in modern Web sites.